Compare Freshworks Inc (FRSH) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Zimmer Biomet Holdings Inc — how do they compare? Freshworks Inc trades at $13.92 (market cap $3.56B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.8× Freshworks Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FRSH | ZBH | |
|---|---|---|
Market Cap | $3.56B | $16.95B |
Volume | 9,066,454 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $13.92 | $103.98 |
52-Week Low | $6.88 | $79.58 |
Typical Hold Time | 39 Days | 89 Days |
Enterprise Value | $2.93B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.92, up 2.35% today, with strong technical momentum and bullish moving averages. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains robust at 16% year-over-year, while valuation metrics show a P/E of 21.63 and P/S of 4.28. Recent developments include FedRAMP certification progress and leadership appointments.
The outlook appears positive with analyst consensus at $14.60 price target and 50% buy ratings. Key opportunities include AI monetization and enterprise growth, while risks involve competitive SaaS market pressure and the need to sustain recent profitability gains amid ongoing investments.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
